ALT Overview
Upcoming Projects (ALT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ALT)
-
Examining the effect of Pemvidutide on Cardioinflammatory Lipids presented at the American Diabetes Association annual meeting
Ticker: ALT
Executed On: Jul 11, 2024 at 09:30 AM EDT -
A Second Opinion: Looking at the potential of Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist for patients with obesity
Tickers: ALT, LLY, NVO
Executed On: Jan 18, 2024 at 10:00 AM EST -
Looking at the potential of Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist for patients with obesity
Tickers: ALT, LLY, NVO
Executed On: Jan 11, 2024 at 09:30 AM EST -
A third discussion on the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Nov 03, 2022 at 11:30 AM EDT -
A second discussion on the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Nov 01, 2022 at 03:00 PM EDT -
Discussing the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Oct 28, 2022 at 02:45 PM EDT
Upcoming & Overdue Catalysts (ALT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ALT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
